Anti-reflux medication use in preterm infants

Haslina Binti Abdul Hamid1,2, Lisa Szatkowski1, Helen Budge1 and Shalini Ojha1,3✉
© The Author(s) 2021

BACKGROUND: Current recommendations do not support the use of anti-reflux medications to treat gastro-oesophageal reflux disease (GORD) among preterm infants.

OBJECTIVE: To describe the prevalence of GORD and the use of anti-reflux medications amongst very preterm infants (<32 weeks' gestational age (GA)) in neonatal units in England and Wales.

DESIGN: Retrospective cohort study using the National Neonatal Research Database.

RESULTS: Among 58,108 infants [median GA (IQR) 29 (27–30) weeks], 15.8% (n = 9191) had a diagnosis of GORD and 36.9% (n = 12,446) received anti-reflux medications. Those who received anti-reflux medications were more preterm (GA, median (IQR): medications, 28 (26–30) vs. no medications, 30 (28–31); p < 0.001) and had lower birth weight [mean (SD): medications, 1124 g (354) vs. no medications, 1265 g (384); p < 0.001]. Most (57%, n = 12,224) received Gaviscon, or Histamine-2 Receptor Antagonist (H2RA) (56%, n = 11,959). Over time, prokinetic use has declined substantially, the use of H2RAs and Gaviscon has reduced although they continue to be used frequently, whilst the use of PPIs has increased.

CONCLUSIONS: Anti-reflux medications are frequently prescribed in very preterm infants, despite evidence to suggest that they are not effective and may be harmful. Clear guidelines for diagnosing GORD and the use of anti-reflux medications are required to rationalise the pharmacological management of GORD in preterm infants.

Pediatric Research (2022) 92:520–525; https://doi.org/10.1038/s41390-021-01821-y

IMPACT:

- Anti-reflux medications are frequently prescribed, often without a diagnosis of gastro-oesophageal reflux disease, to very preterm infants while in the neonatal unit and at discharge.
- Half of the infants born at <28 weeks' gestational age receive anti-reflux medications in hospital and a quarter are discharged home on them.
- Although the use of prokinetics declined following alerts of adverse events, histamine2-receptor antagonists and alginates such as Gaviscon continue to be used and the use of proton-pump inhibitors has increased more than 2-fold.

INTRODUCTION

Gastro-oesophageal reflux (GOR), the passage of gastric contents into the oesophagus, is common in preterm infants. 1 It usually occurs due to the relatively abundant volume of liquid intake and supine feeding position. However, GOR can worsen and lead to troublesome signs and symptoms i.e., gastro-oesophageal reflux disease (GORD).

Determination of the exact prevalence of GOR versus GORD is challenging because of an unclear distinction between physiologic and pathologic reflux. Additionally, the terms “reflux”, "acid-reflux", and GORD are often used interchangeably by healthcare professionals as well parents and families of infants. 2 In a retrospective cohort study of 33 neonatal units in the USA, 3 there was a wide variation between the units in the proportion of preterm infants who received a diagnosis of GORD based on the International Classification of Diseases (ICD-9). Approximately 10% of infants born at 22–36 weeks gestational age (GA) were recorded to have GORD with diagnosis prevalence ranging from 2.4 to 29.9% across the included neonatal units.

Anti-reflux medications, including Histamine-2 receptor antagonists (H2RA) and proton-pump inhibitors (PPI), are unlicensed for use in neonates in the UK and many other countries, 4 though off-label use is frequently reported. 5 Antacids and other acid-suppressing agents may reduce gastric acidity but anti-reflux medications do not improve signs/symptoms of GORD and their use has been associated with increased risks of adverse outcomes including necrotising enterocolitis (NEC) and infections. 6 The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and European Society for Paediatric Gastroenterology Hepatology and Nutrition (NASPGHAN and ESPGHAN combined) clinical practice guidelines 1 suggests non-pharmacological approaches to GORD before pharmacological therapy. Similarly, the American Academy of Paediatrics recommends that anti-reflux medications should be used with caution, if

1Population and Lifespan Sciences, School of Medicine, University of Nottingham, Nottingham, UK. 2Dietetic Programme, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, 50300 Kuala Lumpur, Malaysia. 3Neonatal Unit, University Hospitals of Derby and Burton, Derby DE23 3DT, UK. ✉email: shalini.ojha@nottingham.ac.uk

Received: 29 July 2021 Revised: 28 September 2021 Accepted: 1 October 2021
Published online: 29 October 2021
at all, in preterm infants due to lack of evidence of efficacy and possible significant harm.7

Despite these recommendations, anti-reflux medications are frequently used. A large retrospective study including infants admitted to neonatal units in 43 children’s hospitals in the USA reported that 24% received either an H2RA or PPI with the extremely preterm infants being the most likely to receive these medicines.8 Similarly, Malcolm et al.9 reported that a quarter of extremely low birth weight infants who were enrolled in the National Institute of Child Health and Human Development Neonatal Network generic database in 2002–2003 were discharged from the hospital with anti-reflux medications.

In the UK, two survey studies of neonatal healthcare professionals, in 200410 and 2018,11 revealed that clinicians reported frequently prescribing anti-reflux medications in neonatal units. Dhillon and Ewer10 reported that, in 2004, nearly all respondents frequently prescribed anti-reflux medications. The 2018 survey showed that the use of anti-reflux medications is popular11 despite the increasing evidence of lack of efficacy and possible harm. Both studies analysed the use of medications as reported by clinicians. There are no studies that have analysed the prevalence of GORD diagnosis and the actual use of anti-reflux medications in neonatal units in the UK.

In this study, we aimed to describe the prevalence of GORD diagnosis and use of anti-reflux medications amongst very preterm infants in England and Wales. We also aimed to analyse the types of medications used, duration and trend of medications use between 2010 and 2017.

METHODS

We conducted a retrospective observational cohort study using the data held in the National Neonatal Research Database (NNRD). The NNRD is a repository of clinical data of admissions to the 200 neonatal units in England, Wales and Scotland that make up the UK Neonatal Collaborative.12

Identification of study cohort

Infants born <32 weeks’ gestational age (GA), in England and Wales from 2010 until 2017, whose data are held in the NNRD were included. Infants were excluded if they were missing data on sex, birth weight, month of birth or one or more days of care, were a late admission to neonatal care (>24 h) or had an extreme birth weight for GA (Z-score ≥ +4 SD or ≤ −4 SD).

Data extraction

Records of GORD were extracted by searching for specified terms in the “principal diagnosis at admission”, “daily diagnoses” and “diagnoses at discharge” fields. A list of anti-reflux medications for GORD was prepared according to the British National Formulary (BNF) and included Ranitidine (H2RA), Omeprazole and Lansoprazole (PPI), Domperidone, Metoclopramide, and Erythromycin (Prokinetics). Indicator variables were created for each day of care to show whether an infant was prescribed any of the anti-reflux medications. Code lists are available from the authors on request.

Table 1 shows that 15.8% (n = 9191) of total infants had any record of GORD. Infants first received GORD diagnosis at median (IQR) PMA of 36 (33–38) weeks. Infants with a diagnosis of GORD were more preterm than infants without a diagnosis [GA, median (IQR): GORD, 28 weeks (26–30) vs. no GORD, 29 weeks (27–31); p < 0.001], had lower birth weight [mean (SD): GORD, 1114 g (337) vs. no GORD, 1232 g (384); p < 0.001] and fewer were female [n (%): GORD, 3856 (42.0%) vs. no GORD, 22,740 (46.5%); p < 0.001].

Of all the infants, 36.9% (n = 21,446) received anti-reflux medications during admission and 18.2% were receiving them at discharge (Table 1). However, among those who received anti-reflux medications, only 39.6% had a diagnosis of GORD. The PMA (median (IQR)) at first prescription of an anti-reflux medication was 32 weeks (30–34) and the treatments were continued for a median (IQR) duration of 20 days (9–37). 49.3% (n = 8634/17,501) of extremely preterm infants received anti-reflux medications during admission and 24.9% (n = 4352/17,501) were receiving them at discharge. Infants who received anti-reflux medications were more preterm [GA, median (IQR): medications, 28 (26–30) vs. no medications, 30 (28–31); p < 0.001], had lower birth weight [mean (SD): medications, 1124 g (354) vs. no medications, 1265 g (384); p < 0.001] and fewer were female [n (%): medications, 9172 (42.8%) vs. no medications, 17,442 (45.5%); p < 0.001].

Table 2 shows that among all infants who received anti-reflux medications (36.9%, n = 21,466), the largest number had Gaviscon (57%, n = 12,224) followed by H2RA (55.8%, n = 11,959), prokinetics (45.4%, n = 9734) and PPI (16.2%, n = 3480). The use of these medications among the subgroups of <28 weeks’ and 28–32 weeks’ GA is given in Table 2. Extremely preterm infants received all types of medications more frequently and for longer. During their stay, 11.4% (n = 6624) infants received two and 6.4% (n = 3687) received three types of anti-reflux medications. 16.7% (n = 9694) of infants received two or more anti-reflux...
medications on the same day of care and 8.6% (n = 4986) of infants were on two or more anti-reflux medications at discharge.

The change in prescribing of anti-reflux medications between 2010 and 2017 is shown in Fig. 1. The use of prokinetics sharply declined after 2013 (from 23.7% in 2013 to 6.9% in 2017). There was a smaller reduction in the use of H2RAs after 2013 (from 23.7% in 2013 to 6.9% in 2017). There was a linearly decreasing trend in the use of Gaviscon over the time period (from 23.7% in 2013 to 17.9% in 2017). There was a smaller reduction in the use of H2RAs after 2013 (from 23.7% in 2013 to 6.9% in 2017). There

DISCUSSION

Anti-reflux medications were prescribed to 37% of infants born at <32 weeks’ GA in England and Wales and over 18% were discharged home on these medicines. We found that, on average, anti-reflux medications are started at 32 weeks’ PMA and given for 3 weeks. Our findings show that anti-reflux medication use is more prevalent amongst extremely premature infants. Half of the infants born at <28 weeks’ GA received anti-reflux medication in hospital and a quarter at discharge. This group also received anti-reflux medications for, on average, 9 days more compared to the infants born at 28–31 weeks’ GA.

A wide range of clinical signs/symptoms amongst preterm infants are linked to GORD but none are pathognomonic making it difficult to diagnose clinically. In this database, a diagnosis of GORD was reported in 16% of infants born at <32 weeks’ GA. Previous estimates from UK survey data\textsuperscript{10} report a higher prevalence at 22% in infants born at <34 weeks’ GA. Such surveys, however, report the incidence as estimated by the responding clinician and therefore may not represent true prevalence. We found a lower prevalence reported in the NNDR among <32 weeks’ GA infants while Jadcherla et al.\textsuperscript{3}, in a study from 33 hospitals in the United States, reported that 10% of all preterm infants (≤37 weeks GA) had a diagnosis of GORD. The information available in the NNDR does not include how the diagnosis was made and whether any investigations or diagnostic tools were used to determine the presence and severity of GORD. Investigations such as pH monitoring, multichannel intraoesophageal impedance monitoring, contrast fluoroscopy, endoscopy and biopsy are infrequently used for diagnosis in UK neonatal practice and most cases, are diagnosed based on clinical features or clinical features and a therapeutic trial with anti-reflux medications.\textsuperscript{10,11} Although pH monitoring is available in most neonatal units, less than a third report using it\textsuperscript{10} possibly because it may not be a reliable marker of GORD in preterm infants. The stomach pH of preterm infants is rarely <4 due to frequent milk feeding and a higher baseline pH.\textsuperscript{7} Moreover, higher acidity in the

### Table 2. Types of anti-reflux medication and number of days prescribed in infants born at <32 weeks’ gestational age in England and Wales from 2010 to 2017.

| Types of medications and number of days prescribed | Total infants n = 21,466 | <28 weeks’ gestation n = 8634 | 28–31 weeks’ gestation n = 12,812 |
|---------------------------------------------------|--------------------------|-------------------------------|----------------------------------|
| Gaviscon, n (%)                                   | 12,224 (57.0)            | 4467 (51.7)                   | 7757 (60.5)                      |
| Number of days, median (IQR)                     | 17 (8–29)                | 21 (10–37)                    | 15 (8–25)                       |
| PPI, n (%)                                        | 3480 (16.2)              | 1736 (20.1)                   | 1744 (13.6)                     |
| Number of days, median (IQR)                     | 20 (10–34)               | 24 (11–41)                    | 18 (9–29)                       |
| H2RA, n (%)                                       | 11,959 (55.8)            | 5533 (64.1)                   | 6426 (50.2)                     |
| Number of days, median (IQR)                     | 15 (6–30)                | 17 (7–35)                     | 14 (6–26)                       |
| Prokinetics, n (%)                                | 9734 (45.4)              | 4231 (49.0)                   | 5503 (43.0)                     |
| Number of days, median (IQR)                     | 21 (10–37)               | 27 (12–48)                    | 19 (9–31)                       |

PPI proton-pump inhibitor, H2RA H2 receptor antagonists, IQR interquartile range.

Fig. 1  Trends in prescribing anti-reflux medications among infants born at <32 weeks’ gestational age in England and Wales from 2010 to 2017. H2RA histamine-2 receptor antagonists, PPI proton-pump inhibitors.

### Fig. 1
Trends in prescribing anti-reflux medications among infants born at <32 weeks’ gestational age in England and Wales from 2010 to 2017. H2RA histamine-2 receptor antagonists, PPI proton-pump inhibitors.

---

H. Binti Abdul Hamid et al.
oesophageal peristaltic velocity as well as a shorter oesophagus length compared to those born at <32 weeks' GA. The US study recorded median (IQR) treatment duration of 15 (6–35) days but this included preterm infants of 26–36 weeks GA. The longer use of medications among extremely preterm infants could possibly be due to a more prolonged course of GORD due to greater immaturity or because they usually stayed longer in the neonatal unit which opens a longer window of opportunity for medication use as compared to those who were born at later gestations.

It was alarming to note the high use of prokinetics which was prescribed to 45% of the cohort considering that the warning issued by the Food and Drug Administration (FDA) in 2009 and by the European Medicines Agency (EMA) in 2013 which clearly stated that their potential side effects outweigh the possible benefits of these medications for the treatment of GORD in infants <12 months of age. It was, therefore, reassuring that the use has decreased significantly, particularly since 2013, perhaps in keeping with the release of the EMA statement and, later, the UK Medicine and Healthcare products Regulatory Authority (MHRA) announcement on the risk of adverse cardiac events with domperidone.

The use of H2RAs and Gaviscon also declined after 2013, although not as rapidly. At this time, emerging evidence suggested that the use of H2RA is associated with higher risks of adverse effects including infections and NEC, although this was already mentioned in earlier guidelines. Gaviscon, perhaps seen as more innocuous due to lack of evidence of such associations also continues to be used frequently. It can decrease the number of acidic GOR episodes, total oesophageal acid exposure and the frequency of regurgitation events but there is no evidence to show that it alleviates clinical signs and symptoms.

The use of PPIs has increased more than twofold during the study period. A study conducted by Omari et al. showed that omeprazole, a PPI, is effective in reducing the frequency of acid reflux episodes and oesophageal acid exposure but has no impact on clinical signs/symptoms in preterm infants. Moore et al. showed that omeprazole reduced the reflux index as compared to placebo, but changes in clinical features were the same in both groups. These findings are similar to studies using other PPIs such as lansoprazole and esomeprazole.

The use of the NNDR as source data has limitations as it is not used for primary prescribing, and diagnoses are not recorded in a standardised manner such as using ICD codes. There is a risk of data entry errors and missing data. The lower prevalence in NNDR data than the use of anti-reflux medications could also reflect diagnoses not recorded or may represent the lack of formal diagnosis. Additionally, due to the limited information included in the database, we are unable to investigate the details of these prescriptions including the dose and frequency of administration, adverse events, response to medications, and why they were stopped which are all vital information required to assess the rational use of any medication. However, NNDR is the only large database of neonatal data in the UK. The robustness and validity of NNDR data have been previously demonstrated and it is increasingly used for research.

The use of this database allowed us to analyse data from over 58,000 infants born at <32 weeks’ GA representing almost all the eligible population in England and Wales from 2010 to 2017. To our knowledge, this is the first and largest attempt in analysing the prevalence of GORD diagnosis and the prescriptions of anti-reflux medications in England and Wales with data from 200 neonatal units. The results provide...
valuable information on the use of anti-reflux medications in a large population over a long period of time. GORD remains an area fraught with diagnostic and management conundrums and the high prevalence of use of medications despite the lack of evidence of benefit and associations with potential harm, reflects these uncertainties. While large randomised controlled trials are required to evaluate the benefits and harms of using anti-reflux medications in preterm infants, such studies cannot be performed without some clarity or consensus on how to identify infants who have pathological GORD. When perception of “troublesome” symptoms are used to diagnose and treat GORD, trials show no evidence of benefit. Objective determination of diagnosis such as using the acid reflux index can identify infants with true oesophageal acid exposure but do not correlate with clinical signs and symptoms. Additionally, these investigations are not used routinely in the UK and therefore findings from studies using such methods of diagnosis may not readily translate to change in practice. Pragmatic studies that investigate methods of identifying infants thought to have “troublesome” GORD, tool to monitor progression of signs and symptoms attributed to GOR, and evaluation of practices that could reduce the use of anti-reflux medications may help achieve rational treatment for preterm infants.

CONCLUSION
Our findings suggest that anti-reflux medications are frequently prescribed in very preterm infants despite evidence suggesting that they are not effective and may be harmful. Further research and clear guidelines for diagnosing GORD and for rationalising the pharmacological management of GORD are required.

DATA AVAILABILITY
Data are available from the corresponding author upon request.

REFERENCES
1. Rosen, R. et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr. 66, 516–554 (2018).
2. The National Institute for Health and Care Excellence (NICE). Gastro-oesophageal Reflux Disease in Children and Young People: Diagnosis and Management (2019).
3. Jadcherla, S. R. et al. Practice variance, prevalence, and economic burden of premature infants diagnosed with GORD. Hosp. Pediatr. 3, 335–341 (2013).
4. BMJ Group, Pharmaceutical Press, and RCPCH Publications, London. Paediatric Formulary Committee. BNF for Children (online) http://www.medicinescomplete.com (2019).
5. Barney, C. K. et al. Lansoprazole, ranitidine, and metoclopramide: comparison of practice patterns at 4 level III NICUs within one healthcare system. Adv. Neonatal Care Off. J. Natl Assoc. Neonatal Nurses 9, 129–131 (2009).
6. Santos, V. S. et al. Association between histamine-2 receptor antagonists and adverse outcomes in neonates: a systematic review and meta-analysis. PLoS ONE 14, e0214315 (2019).
7. Eichenwald, E. C. Diagnosis and management of gastroesophageal reflux in preterm infants. Pediatrics 142, 11 (2018).
8. Slaughter, J. L., Stenger, M. R., Reagan, P. B. & Jadcherla, S. R. Neonatal histamine-2 receptor antagonist and proton pump inhibitor treatment at United States Children’s Hospitals. J. Pediatr. 174, 63–70.e3 (2016).
9. Malcolm, W. F. et al. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics 121, 22–27 (2008).
10. Dhillon, A. & Ewer, A. Diagnosis and management of gastro-oesophageal reflux in preterm infants in neonatal intensive care units. Acta Paediatr. 93, 88–93 (2007).
11. Rossor, T., Andradi, G., Bhat, R. & Greenough, A. Investigation and management of gastro-oesophageal reflux in United Kingdom neonatal intensive care units. Acta Paediatr. 107, 48–51 (2018).
12. Gale, C. & Morris, I. The UK National Neonatal Research Database: using neonatal data for research, quality improvement and more. Arch. Dis. Child.—Educ. Pract. Ed. 101, 216–218 (2016).
13. Gulati, I. K. & Jadcherla, S. R. Gastroesophageal reflux disease in the neonatal intensive care unit infant: who needs to be treated and what approach is beneficial? Pediatr. Clin. North Am. 66, 461–473 (2019).
14. Shaker, F. M. et al. Decreasing inappropriate use of antireflux medications by standardizing gastroesophageal reflux disease management in NICU. Pediatr. Qual. Saf. 6, e394 (2021).
15. Funderburk, A. et al. Temporal association between reflux-like behaviors and gastroesophageal reflux in preterm and term infants. J. Pediatr. Gastroenterol. Nutr. 62, 556–561 (2016).
16. Vandenplas, Y. et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J. Pediatr. Gastroenterol. Nutr. 49, 498–547 (2009).
17. Terrin, G. et al. Ranitidine is associated with infections, necrotizing enterocolitis, and focal outcome in newborns. Pediatrics 129, e40–e45 (2012).
18. Bilali, A., Galanis, P., Bartoscas, C., Sparos, L. & Velonakis, E. H2-blocker therapy and incidence of necrotizing enterocolitis in preterm infants: a case-control study. Pediatr. Neonatol. 54, 141–142 (2013).
19. Corvaglia, L. et al. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants. Aliment Pharm. Ther. 33, 466–470 (2011).
20. Atasay, B., Erdeve, O., Arsan, S. & Turmen, T. Effect of sodium alginate on acid gastroesophageal reflux disease in preterm infants: a pilot study. J. Clin. Pharmacol. 50, 1267–1272 (2010).
21. Kwok, T. C., Ojha, S. & Darling, J. Feed thickener for infants up to six months of age with gastro-oesophageal reflux. Cochrane Database Syst. Rev. 12, CD003211 (2017).
22. Omari, T. I., Haslam, R. R., Lundborg, P. & Davidson, G. P. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J. Pediatr. Gastroenterol. Nutr. 44, 41–44 (2007).
23. Moore, D. J. et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J. Pediatr. 143, 219–223 (2003).
24. Davidson, G. et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J. Pediatr. 163, 692–698.e2 (2013).
25. Orenstein, S. R., Hassell, E., Furmagha-Jablonska, W., Atkinson, S. & Raanan, M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J. Pediatr. 154, 514–520.e4 (2009).
26. Sand, L. et al. Observational cohort study of changing trends in non-invasive ventilation in very preterm infants and associations with clinical outcomes. Arch. Dis. Child. Fetal Neonatal Ed. https://doi.org/10.1136/archdischild-2021-322390 (2021).
27. Jadcherla, S. R. et al. Role of feeding strategy bundle with acid-suppressive therapy in infants with esophageal acid reflux exposure: a randomized controlled trial. Pediatr. Res. 89, 645–652 (2021).
28. Dermsyhi, E., Mackie, C., Kigozi, P., Schoonakker, B. & Darling, J. Antacid therapy for gastroesophageal reflux in preterm infants: a systematic review. BMJ Paediatr. Open 2, e000287 (2018).

ACKNOWLEDGEMENTS
Electronic patient data recorded at participating neonatal units that collectively form the United Kingdom Neonatal Collaborative are transmitted to the Neonatal Data Analysis Unit to form the National Neonatal Research Database (NRRD). We are grateful to all the families that agreed to the inclusion of their baby’s data in the NRRD, the health professionals who recorded data, and the Neonatal Data Analysis Unit team.

AUTHOR CONTRIBUTIONS
H.B.A.H., S.O., L.S. and H.B. conceptualised and designed the study and reviewed and revised the manuscript. H.B.A.H. performed the data analysis and drafted the initial manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

FUNDING INFORMATION
H.B.A.H. is supported by a Ph.D. scholarship from the Ministry of Higher Education Malaysia and Universiti Kebangsaan Malaysia (UKM).
COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL
Ethical approval was obtained from the Yorkshire & The Humber—Leeds East Research Ethics Committee and Health and Care Research Wales (HCRW) (REC reference: 18/YH/0209; Date of approval: 25 May 2018).

CONSENT TO PARTICIPATE
Informed consent was not asked from individuals whose data were included in this study as the historical data used were held in the pre-existing, REC-approved NNRD. Data held in the NNRD are de-identified and no patient identifiers were used in this study.

CONSENT FOR PUBLICATION
Publication consent was not asked from individuals whose data were included in this study as the historical data used were held in the pre-existing, REC-approved NNRD. Data held in the NNRD are de-identified and no patient identifiers were used in this study.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Shalini Ojha.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021